Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
Likang is planning to offer this product for around $21,000 — a fraction of the price that Western companies like Merck or Moderna would offer for similar products.
- Simplified Text
-
Likang plans to offer cancer vaccine for around $21000
- Confidence Score
- 0.800
- Claim Maker
- The author
- Context Type
- Opinion Piece
- Context Details
-
{ "price": "$21000", "company": "Likang Life Sciences" } - Subject Tags
- UUID
- 9fdaec3e-3412-4bd3-959f-4b4cc69b8001
- Vector Index
- ✗ No vector
- Created
- September 11, 2025 at 9:29 PM (2 days ago)
- Last Updated
- September 11, 2025 at 9:29 PM (2 days ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
51
claims
🔥
2 days ago
https://www.nytimes.com/2025/08/17/opinion/china-biotech.html?campaign_id=9&emc=edit_nn_20250817&instance_id=160714&nl=the-morning®i_id=122976029&segment_id=204065&user_id=b25c5730c89e0c73f75709d8f1254337
China's biotech sector is rapidly expanding, offering cheaper and faster drug manufacturing. This challenges US dominance, sparking debate on competition and collaboration.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.